Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523100 | 1.00 | KCNN4 (0.43) | KCNN4ALDH1A1ALOX15ESR1ESR2 | |
| SCHEMBL12620700 | 0.85 | ALDH1A1 (0.50) | KCNN4ALDH1A1ALOX15MAPK1MAPT | |
| SCHEMBL364200 | 0.84 | SMN1; SMN2 (0.34) | KCNN4ALDH1A1CYP1A2MAPTKMT2A | |
| SCHEMBL363274 | 0.82 | NPC1 (0.35) | KCNN4KMT2ATSHR | |
| SCHEMBL365534 | 0.82 | NPC1 (0.35) | KCNN4KMT2ATSHR | |
| SCHEMBL3520335 | 0.79 | KCNN4 (0.42) | KCNN4ALDH1A1ALOX15CYP1A2CYP2C9 | |
| SCHEMBL3520337 | 0.79 | KCNN4 (0.42) | KCNN4ALDH1A1ALOX15CYP1A2CYP2C9 | |
| SCHEMBL364047 | 0.78 | KCNN4 (0.31) | KCNN4ALDH1A1 | |
| SCHEMBL3498120 | 0.77 | ALDH1A1 (0.40) | ALDH1A1ALOX15ESR1ESR2CYP3A4 | |
| SCHEMBL3498122 | 0.77 | ALDH1A1 (0.40) | ALDH1A1ALOX15ESR1ESR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709533-B2 | Imines as ion channel modulators | ICAGEN, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1861356-A1 | IMINES AS ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20060178346-A1 | Imines as ion channel modulators | ICAGEN, INC. (US) | 2006-08-10 | — | — | US | disclosed |
| WO-2006084031-A1 | IMINES AS ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178346-A1 | Imines as ion channel modulators | KCNN1, KCNN3, KCNN2 | KCNN4 4/4885ALDH1A1 3494/4885ALOX15 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.